We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
-$290M
Cap. Flow %
-26.37%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.87%
2 Financials 0.19%
3 Industrials 0.07%
4 Consumer Staples 0.03%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTGN icon
51
VistaGen Therapeutics
VTGN
$9.55M
$2.35M 0.21%
+70,529
New +$2.33M
ARAV
52
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.19M 0.2%
165,517
+47,634
+40% +$613K
DERM
53
PUT
DELISTED
Dermira, Inc.
DERM
$2.13M 0.19%
+766
New +$20.3K
OCGN icon
54
Ocugen
OCGN
$420M
$1.96M 0.18%
15,918
+7,890
+98% +$965K
MNKD icon
55
PUT
MannKind Corp
MNKD
$1.21B
$1.9M 0.17%
8,169
+2,121
+35% +$7.24K
SLNO
56
DELISTED
Soleno Therapeutics
SLNO
$1.65M 0.15%
+61,007
New +$1.76M
PRTA icon
57
PUT
Prothena Corp
PRTA
$448M
$1.62M 0.15%
+431
New +$21.9K
AMAG
58
DELISTED
AMAG Pharmaceuticals
AMAG
$1.57M 0.14%
118,864
+38,756
+48% +$584K
BNBX
59
DELISTED
BNB PLUS CORP
BNBX
$1.48M 0.14%
+2
New +$2.81M
ASXC
60
DELISTED
Asensus Surgical, Inc.
ASXC
$1.37M 0.12%
+54,469
New +$1.68M
IDXG
61
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$1.35M 0.12%
+131,929
New +$1.59M
KYNB
62
CALL
Kyntra Bio
KYNB
$28.2M
$1.3M 0.12%
11
-44
-80% -$55.2K
ALKS icon
63
PUT
Alkermes
ALKS
$8.47B
$1.28M 0.12%
+234
New +$11.9K
MBOT icon
64
Microbot Medical
MBOT
$113M
$1.27M 0.12%
83,333
-94
-0.1% -$1.6K
DERM
65
DELISTED
Dermira, Inc.
DERM
$1.26M 0.11%
+45,304
New +$1.2M
NKTR icon
66
Nektar Therapeutics
NKTR
$2.39B
$1.19M 0.11%
+1,333
New +$788K
ALXN
67
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
$1.15M 0.1%
+96
New +$11.7K
SIOX
68
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.13M 0.1%
268
+109
+69% +$4.89K
PRQR icon
69
ProQR Therapeutics
PRQR
$248M
$1.12M 0.1%
+347,245
New +$1.25M
ADVM
70
DELISTED
Adverum Biotechnologies
ADVM
$1.05M 0.1%
+30,000
New +$987K
SCPX
71
DELISTED
Scorpius Holdings, Inc.
SCPX
$1M 0.09%
9
+3
+50% +$444K
SIOX
72
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$974K 0.09%
231
-729
-76% -$32.7K
AMRN
73
CALL
Amarin Corp
AMRN
$293M
$970K 0.09%
121
-512
-81% -$35.3K
SGYPW
74
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$946K 0.09%
+4,243
New +$946K
AGEN
75
CALL
Agenus
AGEN
$275M
$932K 0.08%
+146
New +$11.1K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $290M in Q4 2017, closing 66 positions and reducing 51 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 7.3% a quarter earlier, followed by Financials and Industrials.

Against the trend, Sabby Management opened a new position in Odonate Therapeutics, Inc. Common Stock worth $20.6M.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.